Drug intelligence / Profile preview

anti-Grem1 neutralizing antibody

Development stage: Preclinical
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Subcutaneous

Overview

Anti-Grem1 neutralizing antibody is a pharmaceutical drug designed to inhibit the activity of Gremlin1 (Grem1), a protein abundantly secreted by bone marrow mesenchymal stromal cells. Grem1 plays a critical role in the development and progression of multiple myeloma (MM) by promoting the proliferation of MM plasma cells. By neutralizing Grem1, this antibody aims to disrupt the positive feedback loop between MM plasma cells and the bone marrow stroma, thereby reducing tumor burden. Preclinical studies in mouse models of multiple myeloma have shown that treatment with an anti-Grem1 neutralizing antibody can significantly decrease tumor burden.

Other names: anti-grem1anti-grem-1anti-grem 1

Targets

GREM1 (Gremlin-1)

Beyond the preview

Go deeper on anti-Grem1 neutralizing antibody.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on anti-Grem1 neutralizing antibody.

Explore the full profile